[
  {
    "ts": null,
    "headline": "Genmab A/S (GMAB): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Genmab A/S on Gabriel Koh’s Substack. In this article, we will summarize the bulls’ thesis on GMAB. Genmab A/S’s share was trading at $33.87 as of January 13th. GMAB’s trailing and forward P/E were 14.83 and 12.58, respectively according to Yahoo Finance. Genmab is a leading biotechnology company focused […]",
    "url": "https://finnhub.io/api/news?id=a365fccc8221365d68d13fbc31a1899e47faacf1bd644526f0acee2810735645",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768505592,
      "headline": "Genmab A/S (GMAB): A Bull Case Theory",
      "id": 138126653,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Genmab A/S on Gabriel Koh’s Substack. In this article, we will summarize the bulls’ thesis on GMAB. Genmab A/S’s share was trading at $33.87 as of January 13th. GMAB’s trailing and forward P/E were 14.83 and 12.58, respectively according to Yahoo Finance. Genmab is a leading biotechnology company focused […]",
      "url": "https://finnhub.io/api/news?id=a365fccc8221365d68d13fbc31a1899e47faacf1bd644526f0acee2810735645"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death",
    "summary": "Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the JP Morgan Healthcare Conference 2026.",
    "url": "https://finnhub.io/api/news?id=05d144e8b97a7e888d85a95eac6199093ab4e8c2a41a65f746717a4a86351e10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768492587,
      "headline": "JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death",
      "id": 138122855,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Intellia Therapeutics CEO John Leonard explained the circumstances of the patient death at the JP Morgan Healthcare Conference 2026.",
      "url": "https://finnhub.io/api/news?id=05d144e8b97a7e888d85a95eac6199093ab4e8c2a41a65f746717a4a86351e10"
    }
  },
  {
    "ts": null,
    "headline": "Longleaf Partners Fund 2025 Contributors And Detractors",
    "summary": "While 2025 was an underwhelming year for the Fund, there was a clear theme that we can live with in the short term: we did not have enough big winners. Read more here.",
    "url": "https://finnhub.io/api/news?id=8c17eafbf21c2543e93ca2cafc0f6537b81d8a3f6274d856b3326b595ed9faef",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768464000,
      "headline": "Longleaf Partners Fund 2025 Contributors And Detractors",
      "id": 138120249,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/691574517/image_691574517.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "While 2025 was an underwhelming year for the Fund, there was a clear theme that we can live with in the short term: we did not have enough big winners. Read more here.",
      "url": "https://finnhub.io/api/news?id=8c17eafbf21c2543e93ca2cafc0f6537b81d8a3f6274d856b3326b595ed9faef"
    }
  }
]